Kushlinskii N E, Gershtein E S, Naberezhnov D S, Taipov M A, Bezhanova S D, Pushkar' D Yu, Matveev V B, Stilidi I S
N. N. Blokhin National Medical Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russia.
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation, Moscow, Russia.
Bull Exp Biol Med. 2019 Jul;167(3):388-392. doi: 10.1007/s10517-019-04533-w. Epub 2019 Jul 26.
The concentration of kidney injury molecule-1 (KIM-1) was measured in blood plasma of 99 patients with clear-cell carcinoma and 14 patients with benign renal tumors using a Human Serum TIM-1/KIM-1/HAVCR Quantikine ELISA kit. The control group consisted of 15 healthy male and 14 healthy female subjects. KIM-1 levels in blood plasma of patients with cancer or benign renal tumors were significantly higher than in the control (p<0.00001 and p<0.01, respectively). In patients with benign tumors, this parameter was significantly lower than in patients with cancer (p<0.0001). KIM-1 level significantly increased with disease stage (p<0.0001), and even in stage I cancer, it was higher than in the control group (p<0.0001) or in patients with benign tumors (p<0.01). The best sensitivity/specificity ratio for stage I renal cancer detection (81 and 83% respectively) was achieved at cut-off level 77 pg/ml, the sensitivity of detection of for stages II-IV being 97%. Plasma level of KIM-1 increased with increasing the size and area of the primary tumor (T). This parameter was higher in patients with metastasis in regional lymph nodes irrespective of their number (N1 or N2) in comparison with patients without regional metastasis (N0). It is also higher in patients with distant metastasis (M+). In patients with grade III-IV cancer, KIM-1 level was 7-fold higher than in patients with grade I-II tumor (p<0.0001). Thus, KIM-1 can be regarded as a highly sensitive marker for early detection of clear-cell carcinoma.
使用人血清TIM-1/KIM-1/HAVCR Quantikine ELISA试剂盒，对99例透明细胞癌患者和14例良性肾肿瘤患者的血浆进行肾损伤分子-1（KIM-1）浓度测定。对照组由15名健康男性和14名健康女性组成。癌症患者或良性肾肿瘤患者血浆中的KIM-1水平显著高于对照组（分别为p<0.00001和p<0.01）。在良性肿瘤患者中，该参数显著低于癌症患者（p<0.0001）。KIM-1水平随疾病分期显著升高（p<0.0001），即使在I期癌症患者中，其水平也高于对照组（p<0.0001）或良性肿瘤患者（p<0.01）。在临界值为77 pg/ml时，I期肾癌检测的最佳灵敏度/特异性比分别为81%和83%，II-IV期检测的灵敏度为97%。KIM-1的血浆水平随原发肿瘤（T）大小和面积的增加而升高。与无区域转移（N0）的患者相比，区域淋巴结有转移（无论转移数量为N1或N2）的患者该参数更高。远处转移（M+）的患者中该参数也更高。在III-IV级癌症患者中，KIM-1水平比I-II级肿瘤患者高7倍（p<0.0001）。因此，KIM-1可被视为早期检测透明细胞癌的高灵敏度标志物。
